Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD) An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopre ...
Irritable Mood;Huntington's Disease
Drug: SRX246;Drug: Placebo
Azevan Pharmaceuticals
National Institute of Neurological Disorders and Stroke (NINDS);NeuroNEXT Network